TY - JOUR
T1 - Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction
AU - Harada, Kazuhiro
AU - Kikuchi, Ryosuke
AU - Ishii, Hideki
AU - Shibata, Yohei
AU - Suzuki, Susumu
AU - Tanaka, Akihito
AU - Suzuki, Atsuo
AU - Hirayama, Kenshi
AU - Murohara, Toyoaki
N1 - Funding Information:
This work was supported by a grant-in-aid for Young Scientists B (#26860367) and grants from Uehara Memorial Foundation, Nagoya University Hospital Funding for Clinical Research, and Japan Foundation for Applied Enzymology (R. Kikuchi). Mitsui Life Social Welfare Foundation also supported this work (H. Ishii).
Publisher Copyright:
© 2017 The Authors
PY - 2018/6
Y1 - 2018/6
N2 - Background: Vascular endothelial growth factor-A (VEGF-A) promotes neovascularization and is attracting considerable attention as a remarkable risk factor in patients after acute myocardial infarction (AMI). In contrast, the association between VEGF-A165b, which is the main anti-angiogenic isoform of VEGF-A, and adverse clinical outcomes after AMI remains unclear. The present study aimed to investigate the association between serum VEGF-A165b and major adverse cardiac and cerebrovascular events (MACCEs) after percutaneous coronary intervention (PCI) for AMI. Methods: We evaluated 23 patients with AMI who underwent primary percutaneous coronary intervention. VEGF-A and VEGF-A165b levels were measured on admission (day 1) and at days 3, 7, and 30 after PCI. Results: The levels of total VEGF-A tended to be lower, while the ratio of VEGF-A165b to total VEGF-A tended to be higher in patients with MACCEs than in those without. The patients with a high ratio of VEGF-A165b to total VEGF-A had a significantly higher risk of MACCEs using the cut-off values for MACCEs at day 30 after PCI (0.87 vs. 0.25, log-rank test, p = 0.0058). Conclusion: The assessment of VEGF-A165b combined with VEGF-A may be a valuable screening tool for predicting MACCEs in clinical practice.
AB - Background: Vascular endothelial growth factor-A (VEGF-A) promotes neovascularization and is attracting considerable attention as a remarkable risk factor in patients after acute myocardial infarction (AMI). In contrast, the association between VEGF-A165b, which is the main anti-angiogenic isoform of VEGF-A, and adverse clinical outcomes after AMI remains unclear. The present study aimed to investigate the association between serum VEGF-A165b and major adverse cardiac and cerebrovascular events (MACCEs) after percutaneous coronary intervention (PCI) for AMI. Methods: We evaluated 23 patients with AMI who underwent primary percutaneous coronary intervention. VEGF-A and VEGF-A165b levels were measured on admission (day 1) and at days 3, 7, and 30 after PCI. Results: The levels of total VEGF-A tended to be lower, while the ratio of VEGF-A165b to total VEGF-A tended to be higher in patients with MACCEs than in those without. The patients with a high ratio of VEGF-A165b to total VEGF-A had a significantly higher risk of MACCEs using the cut-off values for MACCEs at day 30 after PCI (0.87 vs. 0.25, log-rank test, p = 0.0058). Conclusion: The assessment of VEGF-A165b combined with VEGF-A may be a valuable screening tool for predicting MACCEs in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85044169093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044169093&partnerID=8YFLogxK
U2 - 10.1016/j.ijcha.2018.03.004
DO - 10.1016/j.ijcha.2018.03.004
M3 - Article
AN - SCOPUS:85044169093
VL - 19
SP - 3
EP - 7
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
SN - 2352-9067
ER -